Comparative Pharmacology
Head-to-head clinical analysis: SARCLISA versus VOYXACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SARCLISA versus VOYXACT.
SARCLISA vs VOYXACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
GABAA receptor positive allosteric modulator; a neuroactive steroid that potentiates GABAergic inhibition.
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
Adults: 200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Terminal elimination half-life approximately 37 hours (range 24-51 hours), supporting once-daily dosing with steady-state achieved in 5-8 days.
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Primarily hepatic metabolism via CYP3A4, with 53% of the dose excreted in feces (mainly as metabolites) and 27% in urine (mostly as metabolites); less than 1% excreted unchanged in urine.
Category C
Category C
Monoclonal Antibody, Antineoplastic
Antineoplastic